ArticleAnnals of surgical oncology2025
Higher Neoadjuvant Radiation Dose is Associated with Lower Overall Survival in Resected Esophageal Cancer: A Propensity-Matched National Cancer Database Analysis.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Radiation dose and pathological complete response rate of neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma: a model-based dose-response meta-analysis.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFollowing publication of the Chemoradiotherapy for Esophageal Cancer Followed by Surgery Study (CROSS) trial, neoadjuvant chemoradiation has become standard of care for most esophageal cancer (EC). Patients most commonly receive either 41.4 Gy (per CROSS) or 50-50.4 Gy, but little post-CROSS era data have been reported.
methodsThe National Cancer Database (NCDB) was queried for patients with EC receiving neoadjuvant chemoradiation followed by resection from 2012-2020 (n = 10,810). Patients were grouped by neoadjuvant radiation dose (41.4 Gy or 50-50.4 Gy). Overall survival (OS) was evaluated with Cox proportional hazards modeling following propensity-score matching on the basis of relevant clinicopathologic characteristics.
resultsA total of 10,810 patients were identified, with 1450 (13.4%) receiving 41.4 Gy of radiation and 9360 (86.6%) receiving 50-50.4 Gy. At a median follow-up of 61.6 months, median OS was 59.9 months in patients receiving 41.4 Gy and 45.5 months (P < 0.001) for patients receiving 50-50.4 Gy. Following stratification by posttreatment stage, 41.4 Gy dosing remained associated with improved OS compared with 50-50.4 Gy, but was most pronounced for patients with pCR (median OS 110.0 versus 82.4 months, P < 0.001) and Tis/Stage I residual disease (median OS 92.8 versus 67.2 months, P = 0.02). Propensity matching yielded 1448 patients per group. On multivariable analysis, receipt of 41.4 Gy was independently associated with improved OS (HR 0.82, P < 0.001).
conclusionsLower neoadjuvant radiation dosage is associated with improved OS in resected EC. Until prospective trials are completed, higher radiation doses should be reserved for definitive treatment in patients ineligible for surgery, due to potential harms.
Indexed as
Identifiers
40956536What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.